Shares of Miragen Therapeutics, Inc. (NASDAQ:MGEN) have been assigned an average recommendation of “Buy” from the eight research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $15.13.
A number of research analysts have commented on the stock. B. Riley assumed coverage on shares of Miragen Therapeutics in a research report on Friday, January 5th. They set a “buy” rating and a $15.50 price target on the stock. Zacks Investment Research cut shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Chardan Capital restated a “buy” rating on shares of Miragen Therapeutics in a report on Tuesday, January 16th. Oppenheimer initiated coverage on shares of Miragen Therapeutics in a report on Friday, January 12th. They issued an “outperform” rating and a $13.00 target price on the stock. Finally, Cann restated a “buy” rating and issued a $13.00 target price on shares of Miragen Therapeutics in a report on Friday, February 2nd.
Miragen Therapeutics (NASDAQ MGEN) opened at $5.57 on Friday. Miragen Therapeutics has a 52-week low of $5.01 and a 52-week high of $18.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.11 and a current ratio of 7.11. The company has a market cap of $158.30, a P/E ratio of -0.62 and a beta of 1.44.
In other news, insider Adam Scott Levy bought 9,090 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were purchased at an average price of $5.50 per share, for a total transaction of $49,995.00. Following the completion of the acquisition, the insider now owns 10,540 shares of the company’s stock, valued at $57,970. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bruce Booth bought 545,454 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was purchased at an average price of $5.50 per share, for a total transaction of $2,999,997.00. The disclosure for this purchase can be found here. 44.40% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the company. Seaward Management Limited Partnership bought a new position in shares of Miragen Therapeutics in the third quarter worth approximately $117,000. Russell Investments Group Ltd. bought a new position in shares of Miragen Therapeutics in the third quarter worth approximately $147,000. Wells Fargo & Company MN boosted its holdings in Miragen Therapeutics by 203.8% in the fourth quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after acquiring an additional 11,943 shares in the last quarter. BSW Wealth Partners bought a new stake in Miragen Therapeutics in the third quarter valued at $203,000. Finally, Aveo Capital Partners LLC bought a new stake in Miragen Therapeutics in the fourth quarter valued at $279,000. Hedge funds and other institutional investors own 23.39% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Miragen Therapeutics, Inc. (MGEN) Receives Consensus Recommendation of “Buy” from Analysts” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/24/miragen-therapeutics-inc-mgen-receives-consensus-recommendation-of-buy-from-analysts.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.